Falsified Avastin Have Blinded Patients In Pakistan

Lahore: Dozens of people in Pakistan have lost their sight after being injected with what is suspected to be a falsified version of Roche’s Avastin medicine.

The patients in Punjab province – numbered at 68 according to local media reports – were being treated off-label with Avastin (bevacizumab) for diabetic retinopathy, a sight-robbing complication of diabetes, using product supplied by distributor Genius Advanced Pharmaceutical Services.

The government has since imposed a temporary ban on the sales and distribution of the drug while quality checks are carried out, and two people linked to Genius have been identified and charged, but are on the run.

The Drug Regulatory Authority of Pakistan (DRAP) said in a statement that there had been cases of “loss of vision in diabetic patients have been reported following treatment with Altered/Dispensed/Diluted Avastin injection.”

There have been numerous reports over more than a decade of counterfeit versions of the VEGF-targeting antibody – which is licensed to treat various forms of cancer – being discovered in medicine supply chains around the world, including in the US and Europe.

Analysis of seized samples has revealed that the vials generally contain no active ingredient and are not sterile, meaning that injection into the eye – as occurs with treatment for diabetic retinopathy – could lead to serious infections.

Back in 2010, there was an outbreak of endophthalmitis in Shanghai, China, following the injection of fake Avastin into the eyes of patients with retinal diseases.

In this case, Genius is suspected of repacking and dispensing Avastin injection under unhygienic or non-sterile conditions, and it is not clear yet whether the products itself is genuine or counterfeit.

Related Posts

  • Pharma
  • December 23, 2024
  • 14 views
Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

  • Pharma
  • December 23, 2024
  • 39 views
NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

India-Latin America trade and collaboration prospects discussed at Kerala University conference

India-Latin America trade and collaboration prospects discussed at Kerala University conference

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt